Sandra Stapleton has over 20 years of experience successfully incorporating innovative clinical solutions into the marketplace. She has led strategic, clinical, operations and technology functions, and post acquisition transitional teams. She comes to VIDA from Lexmark International (following acquisition of Claron Technology, Inc.), where she led the imaging platform business, corporate quality and regulatory, and visualization engineering functions for Lexmark. Prior to Claron, Sandra served as VP of Technology at R2 Technology (R2), where she led development of R2's mammography and lung computer-aided detection products, both receiving FDA PMA approval. Sandra received her MSc. in Medical Biophysics from the University of Toronto.
"I'm excited to be joining VIDA's executive team as we advance precision information into clinical practice," said Sandra. "With the clinical evidence supporting its software and services, VIDA is poised to improve the standard of pulmonary care."
VIDA is focused on changing the practice of pulmonary care by empowering the pulmonary clinician with precision informatics. VIDA's suite of software and associated analysis services aid early detection, evaluation, and treatment planning of lung diseases, including lung cancer, emphysema, airway obstructive diseases, and asthma. VIDA's software and services are cleared for clinical use in the United States, Canada, European Union, and Australia. VIDA is headquartered in Coralville, IA, with an additional office in Minneapolis, MN.
Logo - http://photos.prnewswire.com/prnh/20160104/319103LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vida-expands-executive-team-with-appointment-of-chief-operations-officer-300376184.html
SOURCE VIDA Diagnostics, Inc.